Colorectal cancer (CRC) is a global health concern, and despite advances in radiotherapy, endogenous radioresistance in CRC ...

Omega-3 polyunsaturated fatty acids and docosahexaenoic acid appear to be associated with lower age-related macular ...

Synopsys Inc. closed $127.38 short of its 52-week high ($629.38), which the company reached on February 22nd.

The CMA's decision prevents the transaction from advancing to Phase 2 scrutiny, allowing continued collaboration.

Synopsys (SNPS) issued the following statement in response to the UK Competition and Markets Authority provisionally accepting its proposed ...

Electronic design automation firm Synopsys (SNPS) said it is pleased the U.K.'s antitrust agency has provisionally accepted ...

Ansys and Synopsys today announced that Ansys has entered into a definitive agreement for the sale of its PowerArtist™ business to Keysight Technologies, Inc., a global leader in design and simulation ...

The stock's fall snapped a two-day winning streak.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

Smoking increases the likelihood of developing numerous morbidities; however, it remains unclear how this behavior may impact ...

Analyst Joseph Quatrochi of Wells Fargo maintained a Hold rating on Synopsys (SNPS – Research Report), retaining the price target of ...